Sylvie Pollmann

  • Postdoctoral Researcher

More information: visit the Sollid group home page

 

Publications 2019

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721

Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2019)
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732

Publications 2014

Løset GÅ, Berntzen G, Frigstad T, Pollmann S, Gunnarsen KS, Sandlie I (2014)
Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions
Front Oncol, 4, 378
DOI 10.3389/fonc.2014.00378, PubMed 25629004

Publications 2012

Nilssen NR, Frigstad T, Pollmann S, Roos N, Bogen B, Sandlie I, Løset GÅ (2012)
DeltaPhage--a novel helper phage for high-valence pIX phagemid display
Nucleic Acids Res, 40 (16), e120
DOI 10.1093/nar/gks341, PubMed 22539265

Publications 2011

Pollmann S, Stensland M, Halvorsen EH, Sollid LM, Kvien TK, Fleckenstein B, Molberg O (2011)
Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate
Rheumatol Int, 32 (5), 1271-6
DOI 10.1007/s00296-010-1765-y, PubMed 21267570

Publications 2009

Stensland ME, Pollmann S, Molberg Ø, Sollid LM, Fleckenstein B (2009)
Primary sequence, together with other factors, influence peptide deimination by peptidylarginine deiminase-4
Biol Chem, 390 (2), 99-107
DOI 10.1515/BC.2009.019, PubMed 19040354

Publications 2008

Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg Ø (2008)
Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents
Ann Rheum Dis, 68 (2), 249-52
DOI 10.1136/ard.2008.094490, PubMed 18723564

Publications 2007

Halvorsen EH, Pollmann S, Gilboe IM, van der Heijde D, Landewé R, Ødegård S, Kvien TK, Molberg Ø (2007)
Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity
Ann Rheum Dis, 67 (3), 414-7
DOI 10.1136/ard.2007.080267, PubMed 18006540

Textoris-Taube K, Henklein P, Pollmann S, Bergann T, Weisshoff H, Seifert U, Drung I, Mügge C, Sijts A, Kloetzel PM, Kuckelkorn U (2007)
The N-terminal flanking region of the TRP2360-368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation
J Biol Chem, 282 (17), 12749-54
DOI 10.1074/jbc.M611644200, PubMed 17308306

Publications 2002

Sijts A, Sun Y, Janek K, Kral S, Paschen A, Schadendorf D, Kloetzel PM (2002)
The role of the proteasome activator PA28 in MHC class I antigen processing
Mol Immunol, 39 (3-4), 165-9
PubMed 12200048

Sun Y, Sijts AJ, Song M, Janek K, Nussbaum AK, Kral S, Schirle M, Stevanovic S, Paschen A, Schild H, Kloetzel PM, Schadendorf D (2002)
Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells
Cancer Res, 62 (10), 2875-82
PubMed 12019167

Page visits: 3130